Needham & Company LLC Reiterates Buy Rating for Hinge Health (NYSE:HNGE)

Hinge Health (NYSE:HNGE)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $59.00 price objective on the stock. Needham & Company LLC’s price target would suggest a potential upside of 49.22% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Piper Sandler cut their price target on shares of Hinge Health from $71.00 to $60.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. KeyCorp lowered their price objective on Hinge Health from $72.00 to $70.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. Barclays reduced their target price on Hinge Health from $65.00 to $60.00 and set an “overweight” rating on the stock in a research report on Monday, January 5th. Wells Fargo & Company assumed coverage on Hinge Health in a report on Thursday, January 8th. They issued an “overweight” rating and a $68.00 price target for the company. Finally, Canaccord Genuity Group boosted their price target on Hinge Health from $61.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $57.71.

Hinge Health Stock Up 2.0%

NYSE HNGE opened at $39.54 on Wednesday. The firm has a market cap of $3.11 billion and a PE ratio of -3.01. The company has a 50 day moving average price of $43.76 and a 200 day moving average price of $48.80. Hinge Health has a 52 week low of $30.08 and a 52 week high of $62.18.

Hinge Health announced that its board has authorized a stock buyback plan on Wednesday, November 12th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 7.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other news, CFO James Budge sold 44,589 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $47.47, for a total value of $2,116,639.83. Following the completion of the transaction, the chief financial officer directly owned 479,878 shares in the company, valued at $22,779,808.66. This trade represents a 8.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President James Pursley sold 15,000 shares of Hinge Health stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $48.40, for a total value of $726,000.00. Following the sale, the president directly owned 769,778 shares of the company’s stock, valued at $37,257,255.20. This trade represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 2,805,105 shares of company stock valued at $128,216,614.

Institutional Trading of Hinge Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BIT Capital GmbH lifted its position in Hinge Health by 79.3% during the fourth quarter. BIT Capital GmbH now owns 3,316,101 shares of the company’s stock valued at $154,033,000 after purchasing an additional 1,466,577 shares during the period. Vanguard Group Inc. raised its stake in shares of Hinge Health by 110.5% during the 4th quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company’s stock valued at $121,027,000 after buying an additional 1,367,693 shares during the last quarter. Bamco Inc. NY purchased a new position in shares of Hinge Health during the 2nd quarter valued at about $48,943,000. Braidwell LP acquired a new position in shares of Hinge Health in the 3rd quarter valued at about $44,686,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Hinge Health in the second quarter worth about $43,840,000.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q4 beat — Hinge reported a Q4 revenue surge and earnings that materially exceeded estimates, driving investor optimism about near-term growth. Investing.com: Q4 earnings
• Positive Sentiment: 2026 guidance & AI investments — Management outlined a 2026 revenue target (~$732M) and a ~25% revenue growth target, citing expansion of AI-driven care that supports the stronger outlook. FierceHealthcare: 2026 revenue projection
• Positive Sentiment: Analyst support — Citizens JMP reaffirmed a “market outperform” rating and set a $65 price target, signaling substantial upside vs. current levels and backing the post-earnings enthusiasm. Benzinga: Citizens JMP
• Positive Sentiment: More buy-side reinforcement — Needham reiterated a “buy” rating with a $59 target, adding to constructive analyst commentary. TickerReport: Needham
• Neutral Sentiment: Investor materials available — The company published its Q4 earnings presentation and call transcript for detailed checks on margin trends, unit economics and AI investment cadence. Useful for investors wanting to validate guidance assumptions. Seeking Alpha: Earnings presentation
• Neutral Sentiment: Price action / volume — The stock posted a sizable intraday rally with volume well above average, reflecting short-covering and fresh buyer interest; this can amplify volatility in either direction. MSN: Intraday move
• Negative Sentiment: Mixed analyst actions — Barclays lowered its price target from $60 to $52 (still “overweight”), which trims some upside vs. the more bullish targets and highlights lingering analyst caution about sustained margins or execution risk. Benzinga: Barclays
• Negative Sentiment: Profitability risk — Despite the revenue beat, Hinge remains unprofitable (negative P/E), so investors should watch whether revenue growth translates into sustainable margins and cash flow over the next several quarters.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.